Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.
Yale-New Haven Hospital has deployed Vent Multiplexor’s emergency rescue device to offer crisis care co-ventilation to Covid-19 patients.
The device has been developed in alliance with the hospital to deliver individualised emergency care for two adult patients who need ventilation.
It can be useful when two patients are limited to a single mechanical ventilator. The device can co-ventilate people with different disease states, lung sizes and tidal volume requirements, said the company.
Vent Multiplexor medical director Dr Peter Kahn said: “We stand committed to supporting the entire medical community as we urgently look for ways to quickly develop and deploy novel solutions that are desperately needed to overcome the challenges of delivering emergency crisis care during the pandemic, including the unprecedented challenge of delivering individualised patient care using co-ventilation strategies during temporary ventilator shortages.”
The device has been subjected to preclinical testing, along with evaluations of related clinical protocols on critical care ventilators at Yale-New Haven Hospital.
Findings showed encouraging performance of the device, which can independently regulate tidal volumes delivery when two patients are on a single mechanical ventilator.
Under the partnership, Vent Multiplexor will produce the co-ventilation device at cost for Yale-New Haven Hospital, as well as licence the technology for internal use and development by the hospital.
Vent Multiplexor president Todd Higgins said: “We believe the Vent Multiplexor will offer a significant and immediate contribution to emerging crisis care during the Covid-19 epidemic and look forward to our continued collaboration with YNHH as well as local governments, non-profit organisations, and ventilator manufacturers around the world, as we work with the FDA to secure emergency use authorisation.”
The Vent Multiplexor device, manufactured using 3D printing technology, is yet to receive the US Food and Drug Administration (FDA) authorisation.